UroToday13d
Navigating Cancer Care Costs Videos
A Complex Landscape of Out-of-Pocket Expenses - Benjamin Pockros ...
UroToday22h
The Optimal Treatment for Gleason Score 9-10 Prostate Cancer
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday4d
Clinical Implications of the Molecular and Genomic Landscape of Upper Tract Urothelial Carcinoma.
Upper tract urothelial carcinoma (UTUC) is an aggressive entity with treatment strategies mirroring bladder cancer. Genomic and molecular profiling allows for a better characterization of this disease ...
UroToday3d
Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
Reno, Nevada (UroToday.com) Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve ...
UroToday5d
Multiplex Imaging of Localized Prostate Tumors Reveals Altered Spatial Organization of AR-Positive Cells in the Microenvironment - Beyond the Abstract
Our recent investigation into the spatial cellular landscape of localized prostate tumors provides a comprehensive analysis of over 20 androgen receptor (AR)-positive immune and non-immune stromal ...
UroToday4d
Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer.
This review explores the current landscape of treatments which target the DNA damage response (DDR) in metastatic and muscle-invasive bladder cancer. It emphasizes recent clinical trials which ...
UroToday5d
Instrument Failures for the AirSeal device: a Food and Drug Administration MAUDE Database Study
Objective: This study aims to analyze instances of AirSeal device failures reported in the Food and Drug Administration's MAUDE (Manufacturer and User Facility Device) database, focusing on ...
UroToday4d
Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer.
Prostate cancer therapies against androgen receptor (AR) eventually develop lethal resistance; thus, exploring new therapeutic approaches is urgent for prostate cancer treatment. Acetyltransferase ...
UroToday5d
Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis - Beyond the Abstract
Muscle-invasive bladder cancer (MIBC) requires an aggressive treatment strategy that typically involves neoadjuvant chemotherapy (NAC) followed by radical cystectomy with pelvic lymph node dissection.
UroToday5d
Risk Factors for Incontinence-Associated Dermatitis in Critically Ill Patients with Incontinence: A Systematic Review and Meta-analysis.
This systematic review analyzed evidence related to risk factors for Incontinence Associated Dermatitis (IAD) in critically ill incontinent patients. Systematic review and meta-analysis. Eight ...
UroToday4d
Perioperative Complications and In-Hospital Mortality in Paraplegic Radical Cystectomy Patients.
The aim of this study was to test for the association between paraplegia and perioperative complications as well as in-hospital mortality after radical cystectomy (RC) for non-metastatic bladder ...
UroToday5d
Management options for node-positive muscle-invasive bladder cancer.
Localized node-positive bladder cancer is characterized by a high degree of heterogeneity, leading to significant variability in overall survival outcomes among affected individuals. The absence of ...